Home/Pipeline/CYPS317

CYPS317

Psoriasis

DiscoveryActive

Key Facts

Indication

Psoriasis

Phase

Discovery

Status

Active

Company

FibroBiologics

About FibroBiologics

FibroBiologics is a clinical-stage biotech focused on developing fibroblast cell-based therapies for chronic diseases, positioning fibroblasts as a superior alternative to mesenchymal stem cells. The company has established a robust intellectual property portfolio of over 270 patents and has achieved an FDA IND clearance for its lead program in Degenerative Disc Disease. Its strategy hinges on demonstrating clinical proof-of-concept for its fibroblast platform across multiple high-need indications to validate its core technological thesis and unlock significant value.

View full company profile

Therapeutic Areas

Degenerative Disc Disease Multiple Sclerosis Wound Healing Oncology Autoimmune Anti-Aging

Other Psoriasis Drugs

Drug	Company	Phase	Status
Autoimmune psoriasis candidate	Nyrada	Preclinical	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
IL23R program	Acellera	Pre-clinical	Hit-to-Lead
Undisclosed Psoriasis Program	Nepsone	Preclinical	Active
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
TEM-1657 (Oral)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
Laikangqita Monoclonal Antibody	Livzon Pharmaceutical	NDA	Marketing application accepted and granted priority review
CT-P55	Celltrion	Phase 3	Active
JNJ-77242113	Johnson & Johnson	Phase 3	Active